Toby Toward

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Artificial Intelligence

Temporal Lobe Epilepsy

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Renzo Guerrini, Catherine Chiron, Delphine Vandame, Warren Linley, Toby Toward
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. Epilepsia open 9 (2) (2024)
Renzo Guerrini, Catherine Chiron, Delphine Vandame, Warren Linley, Toby Toward
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. Epilepsia open 9 (2) (2024)
Renzo Guerrini, Catherine Chiron, Delphine Vandame, Warren Linley, Toby Toward
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. Epilepsia open (2024)
Renzo Guerrini, Catherine Chiron, Delphine Vandame, Warren Linley, Toby Toward
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. Epilepsia open 9 (2) (2024)
Renzo Guerrini, Catherine Chiron, Delphine Vandame, Warren Linley, Toby Toward
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. Epilepsia open 9 (2) (2024)
Renzo Guerrini, Catherine Chiron, Delphine Vandame, Warren Linley, Toby Toward
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. Epilepsia open 9 (2) (2024)
Renzo Guerrini, Catherine Chiron, Delphine Vandame, Warren Linley, Toby Toward
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. Epilepsia open 9 (2) (2024)